SARS-CoV-2 Spike (1171-1185) 0.5mg
GINASVVNIQKEIDR is an epitope from the SARS-CoV-2 spike protein (1171-1185). It is an epitope suitable for anti-viral targeting.
Catalogue number crb1001823h Molecular Weight 1654.9 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Jiang et al., (2022). SARS-CoV-2 Omicron Variant is Expected to Retain Most of the Spike Protein Specific Dominant T-Cell Epitopes Presented by COVID-19 Vaccines — Worldwide. China CDC Weekly, 4(18): 381. DOI: 10.46234/ccdcw2022.065.
Manufactured in: United Kingdom
The SARS-CoV-2 spike protein is present on the outside of the virus particles and can bind to angiotensin-converting enzyme II (ACE2) present on the host cells. The C-terminal receptor binding domain (RBD) of the spike protein binds to the N-terminal peptidase M2 domain of ACE2. This receptor binding results in the internalisation of the virus-receptor complex and is, therefore the mechanism of entry of SARS-CoV-2 into host cells.
The spike protein residues GINASVVNIQKEIDR (1171-1185) from C have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.